US5560912A - Method for inhibiting growth of helicobacter pylori - Google Patents
Method for inhibiting growth of helicobacter pylori Download PDFInfo
- Publication number
- US5560912A US5560912A US08/266,013 US26601394A US5560912A US 5560912 A US5560912 A US 5560912A US 26601394 A US26601394 A US 26601394A US 5560912 A US5560912 A US 5560912A
- Authority
- US
- United States
- Prior art keywords
- extract
- helicobacter pylori
- cinnamon
- plant
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 38
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 title claims description 6
- 239000000284 extract Substances 0.000 claims abstract description 48
- 241000196324 Embryophyta Species 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 15
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims abstract description 12
- 229940117916 cinnamic aldehyde Drugs 0.000 claims abstract description 12
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000470 constituent Substances 0.000 claims abstract description 12
- KPNHONAEPLEAJL-UHFFFAOYSA-N 2-methoxy-3-phenylprop-2-enal Chemical compound COC(C=O)=CC1=CC=CC=C1 KPNHONAEPLEAJL-UHFFFAOYSA-N 0.000 claims abstract description 10
- KKVZAVRSVHUSPL-UHFFFAOYSA-N o-methoxycinnamic aldehyde Natural products COC1=CC=CC=C1C=CC=O KKVZAVRSVHUSPL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000004615 ingredient Substances 0.000 claims abstract description 3
- 241000723347 Cinnamomum Species 0.000 claims abstract 4
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 21
- 108010046334 Urease Proteins 0.000 abstract description 13
- 238000000338 in vitro Methods 0.000 abstract description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 31
- 235000017803 cinnamon Nutrition 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 235000020230 cinnamon extract Nutrition 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000007882 Gastritis Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 208000002064 Dental Plaque Diseases 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013345 egg yolk Nutrition 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 4
- 206010019375 Helicobacter infections Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 229960003022 amoxicillin Drugs 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229960000210 nalidixic acid Drugs 0.000 description 3
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 2
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 240000002657 Thymus vulgaris Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 229960004645 bismuth subcitrate Drugs 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- NZWPVDFOIUKVSJ-YFKPBYRVSA-N (2s)-2,6-diamino-n-hydroxyhexanamide Chemical compound NCCCC[C@H](N)C(=O)NO NZWPVDFOIUKVSJ-YFKPBYRVSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000132446 Inula Species 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 229960001171 acetohydroxamic acid Drugs 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001621 bismuth Chemical class 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002828 disc diffusion antibiotic sensitivity testing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940079905 intestinal adsorbents bismuth preparations Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
Definitions
- the present invention relates to a new therapeutic application of particular chemical compounds or an extract of a plant containing them, to prepare a pharmaceutical composition useful to inhibit-the growth of pathogenic bacteria. More particularly, the invention relates to the use of said compounds or said extract, to prepare a pharmaceutical composition useful to inhibit the growth of Helicobacter pylori and urease activity of Helicobacter pylori.
- Helicobacter pylori a bacteria isolated in 1982 from the stomach of patients with gastritis lesions and peptic ulceration, is a genus which formerly was related to Camphylobacter.
- Helicobacter pylori bacteria is the most common known cause of peptic ulcers and accounts for the majority of cases. It has been found in the antrum of more than 95% of patients with duodenal ulcers and in at least 75% of those with gastric ulcers. It is now generally accepted that this bacteria is associated with chronic and peptic ulcer disease and even possible with gastric cancer gastritis (Gabriele Geisel et al, Journal of Clinical Microbiology, May, 1990, 930-2).
- Helicobacter pylori appears as a curved or S shaped gram-negative bacteria, its cell wall being smooth adhering closely to the cytoplasmic membrane. To-day, it is well recognized that the grade of Helicobacter pylori colonisation is associated with chronic gastritis and peptic ulceration. It is the general conclusion that the presence of Helicobacter pylori colonisation is of great importance in both the development and chronicity of peptic gastric ulcer disease. According to Marshall B. J. et al (Med.J.Austr.
- Bismuth preparations were successfully used to combat various gastrointestinal disorders. The most commonly used are bismuth subsalicylate and colloidal bismuth subcitrate. Later on, combinations of bismuth salts with antibiotics, such as amoxycillin and metrodinazole, were also suggested. It was demonstrated that colloidal bismuth subcitrate improved dyspepsia by clearing the bacteria and not by any other effect of the drug on the gastrointestinal tract. To-day, it is considered that a triple therapy comprising:
- the invention relates to the use of cinnamaldehyde or methoxycinnamaldehyde or an organic extract solution of the plant Cinnamon to prepare a pharmaceutical composition useful to inhibit the growth of Helicobacter pylori (hereafter referred to H.pylori) in a host containing same, in an amount which is sufficient to inhibit said growth. It was also found, that the above treatment is also useful to inhibit the activity of urease H.pylori both with the whole cells and the enzyme.
- H.pylori Helicobacter pylori
- FIG. 1 shows the inhibition effect of alcohol Cinnamon extracts on three isolates of H.pylori.
- FIG. 2 illustrates the sensitivity of H.pylori to several antibiotics and Cinnamon plant extracts.
- FIG. 3 illustrates the growth of H.pylori on Egg Yolk Emulsion agar with an organic extract of Cinnamon.
- FIG. 4 illustrates the growth of two isolates of H.pylori in liquid medium with an organic extract of Cinnamon.
- FIG. 5 illustrates the inihibition kinetics of H.pylori urease with whole cells and enzyme by an alcohol extract of Cinnamon.
- the invention relates to the use of an organic extract of the plant Cinnamon to prepare a pharmaceutical composition useful to inhibit the growth of H.pylori in a host containing same.
- the above composition which is administered to the host contains the cinnamaldehyde or methoxycinnamaldehyde or an organic extract solution of the plant Cinnamon, being in an amount that is sufficient to inhibit growth of the bacteria in the host.
- the solution of cinnamaldehyde or methoxycinnamaldehyde or said organic extract is provided either in the form of a drink or a capsule.
- Cinnamon is a well known plant growing in many places. It was surprisingly found that many other plants which are known as medical plants and are quite similar to Cinnamon such as Camomile, Garlic, Olive rape, do not possess at all this property, or only to a very limited extent. Furthermore it should be pointed out that extracts of the above medical plants are mentioned in the literature to possess a medicinal property and are even suggested against disturbances in the digestion system.
- the invention relates to a method to inhibit in-vitro the growth of H.pylori bacteria by contacting said bacteria with an organic extract solution of the plant Cinnamon and said main constituents of the plant.
- the invention relates to the use of the main chemical constituents present in the Cinnamon plant and most preferably cinnamaldehyde and methoxycinnamaldehyde, as a composition useful to inhibit the growth of H.pylori in a host containinig same, in an amount which is sufficient to inhibit said growth.
- the inhibition effect was determined in-vitro, using the "Filter paper disc diffusion method" as described by Laura L. Zaika, (journal of Food Safety 9,1988,p.97-118).
- an extract of the plant was deposited on a small filter paper disc having a diameter of 0.5 cm and then placed in the center of a Petri plate containing agar growth medium inoculated with the test microorganism.
- the plate was incubated under microaerophilic conditions in anaerobic jars at 37° C. for 3 to 4 days and observed for microbial growth. If the extract of Cinnamon exerts antimicrobial activity, the microorganism will not grow in an area surrounding the filter paper disc. This clear area, defined as "zone of inhibition” was measured and recorded in mm.
- This method is well-known also for determining the activity of an antibiotic compound, by measuring the zone of inhibition arround a disc containing a sample of the antibacterial compound to be tested.
- the assays used for the bacterial growth inhibition were as follows:
- FIG. 2 there are presented the sensitivity of Helicobacter pylori, as determined by the inhibition diameter, using two organic extracts of Cinnamon (0,05 mg and 0.1 mg dry weight) compared with antibiotics: ampicillin (0.0. mg), tetracycline (0.03 mg), erythromycine (0.015 mg) nalidixic acid (0.03 mg), cotrimoxazole (0.025 mg). In these tests, two isolates of H.pylori were used.
- the solvent used for the extraction of Cinnamon may be selected from a polar or non-polar solvent such as: ethanol, methylene dichloride, petrol ether, etc.
- a polar or non-polar solvent such as: ethanol, methylene dichloride, petrol ether, etc.
- suitable will be the ethanol extract which can be taken as a drink, with or without any additional flavouring ingredients, added in order to improve the taste.
- the solvent used is methylene dichloride or petroleum ether, it is suggested to evaporate all the solvent from the extract and subsequently to extract the dry matter by ethanol.
- a Cinnamon extract was incorporated in a growth medium consisting of
- BHIB Brain Heart Infusion Broth
- FCS Fetal Calf Serum
- urease of Helicobacter pylori Another factor involved in the pathogenic mechanism of the bacteria, is urease of Helicobacter pylori.
- the urease of Helicobacter pylori is well-known as a pathogenic factor and therefore its inhibition is indeed a long-felt need.
- the organic extracts of Cinnamon were also found to be useful to possess the ability for inhibition of the activity of urease Helicobacter pylori, both with the whole cells and the enzyme. Even an alcoholic extract of 3.8 mg/ml Cinnamon, was found to inhibit up to 52.6% of increase activity of whole bacterial cells and at the same extent of bacterial lysate. This was determined using a modified method of Conway as follows: The reaction mixture contained:
- Cinnamon extracts were added to the reaction mixture at different concentrations. The reaction was continued for 30 minutes. After the addition of a saturated solution of potassium carbonate, the ammonia evolved was absorbed by boric acid and finally detected according to the method using the Bertholet reaction.
- FIG. 5 there are presented the graphs of inhibition kinetics of H.pylori urease, with whole cells and enzyme by an alcohol extract of Cinnamon.
- Cinnamon extracts were added to the reaction mixture in concentrations of 8 mg/ml for whole cells and 2 mg/ml for the enzyme solution (on dry substance).
- the reaction time as 60 minutes.After the addition of a saturated solution of potassium carbonate,ammonia was absorbed by a solution of boric acid and detected according to Bertholet reaction. As can be observed, it clearly appears that the alcohol extract of Cinnamon imparts a much higher inhibition for enzyme than that corresponding to the whole cells.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
TABLE 1
______________________________________
Behaviour of antibiotic substances to three
isolates of Helicobacter pylori.
Isolate of H. pylori
Sensitive to Not affected by.
______________________________________
I.sub.1 ampicyllin ceptarin
I.sub.2 nalidixic acid
erytromycin
I.sub.3 erytromycin nalidixic acid
______________________________________
TABLE 2
______________________________________
Inhibition of Helicobacter pylori by various plant extracts.
Inhibition zone (in mm)
Plant extract type
water extract
alcohol extract
______________________________________
Majorane 22 18
Inula 5 12
Rosemary 10 8
Licorice 11 14
Camomille 5 5
Cinnamon 9 47
Laurel 8 8
Melissa 18 14
Thyme 24 19
Sage 10 9
Garlic 5 7
______________________________________
TABLE 3
______________________________________
Inhibition of Helicobacter pylori growth by
various concentrations of two Cinnamon extracts.
Inhibition Zone (mm)
Concentration (μg)
Extract 1
Extract 2
______________________________________
12 20 0
25 41 0
50 71 0
100 80 19
200 >90* 49
400 >90* 63
800 >90* 90
______________________________________
*indicates that a substantial complete inhibition occurred.
TABLE 4
______________________________________
Inhibition of H. pylori growth by some of the
main chemical constituents of Cinnamon plant.
Chemical Concentration
Inhibition zone
constituent (mg/disk) (mm)
______________________________________
Cinnamaldehyde 0.05 45
" 0.1 60
" 0.2 >90*
Methoxycinnamaldehyde
0.2 44
" 0.4 57
" 0.6 68
Terpinen-4-ol 2.0 22
Alpha-pinene 2.0 18
Alpha-terpinene
2.0 17
Benzyl-benzoate
2.0 17
Cinnamic alcohol
0.2 12
" 0.4 20
______________________________________
(* indicates that a substantial complete inhibition occurred).
TABLE 5
______________________________________
Inhibition of Helicobacter pylori urease by Cinnamon extracts.
Concentration of extracts
in reaction Urease activity (%).
mixture mg/ml Whole cells
Enzyme
______________________________________
0.00 100.00 100.00
1.9 7.90
3.8 52.6 5.99
7.6 41.36
11.4 5.42
15.2 30.92
22.8 22.17
38.0 8.00
______________________________________
Claims (7)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/266,013 US5560912A (en) | 1994-06-27 | 1994-06-27 | Method for inhibiting growth of helicobacter pylori |
| EP94401473A EP0689842A1 (en) | 1994-06-27 | 1994-06-29 | Use of an organic extract of cinnamon plant to inhibit growth of helicobacter pylori |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/266,013 US5560912A (en) | 1994-06-27 | 1994-06-27 | Method for inhibiting growth of helicobacter pylori |
| EP94401473A EP0689842A1 (en) | 1994-06-27 | 1994-06-29 | Use of an organic extract of cinnamon plant to inhibit growth of helicobacter pylori |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5560912A true US5560912A (en) | 1996-10-01 |
Family
ID=26137510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/266,013 Expired - Fee Related US5560912A (en) | 1994-06-27 | 1994-06-27 | Method for inhibiting growth of helicobacter pylori |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US5560912A (en) |
| EP (1) | EP0689842A1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753711A (en) * | 1997-03-18 | 1998-05-19 | Collagenex Pharmaceuticals, Inc. | Method for treatment of H. pylori |
| DE19711597A1 (en) * | 1997-03-20 | 1998-09-24 | Pascoe Pharm Praeparate Gmbh | Preparation for treating Helicobacter pylori infections |
| US6187313B1 (en) | 1996-03-26 | 2001-02-13 | Nature's Sunshine Products, Inc. | Composition and method for treating and preventing helicobactor-pylori-associated stomach gastritis, ulcers and cancer |
| US6190667B1 (en) * | 1998-06-30 | 2001-02-20 | Institut Pasteur | Methods of inhibiting Helicobacter pylori |
| US6248551B1 (en) * | 1997-03-28 | 2001-06-19 | Institut Pasteur | Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides |
| US6350468B1 (en) | 1997-12-17 | 2002-02-26 | Axcan Pharma Inc. | Double capsule for the administration of active principles in multiple therapies |
| US6428808B1 (en) * | 1995-05-23 | 2002-08-06 | Smithkline Beecham P.L.C. | Pharmaceutical composition prepared by addition of a flavor vehicle to a medicament |
| US6638523B1 (en) * | 1999-10-27 | 2003-10-28 | Nagase & Company, Ltd. | Method of treating ulcers |
| US20040009956A1 (en) * | 2002-04-29 | 2004-01-15 | Dehua Pei | Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic |
| US20050008690A1 (en) * | 2002-04-10 | 2005-01-13 | Miller Fred H. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US20110195938A1 (en) * | 2010-02-09 | 2011-08-11 | Baker Hughes Incorporated | Process for preventing or mitigating biofouling |
| US10174239B2 (en) | 2010-02-09 | 2019-01-08 | Baker Hughes, A Ge Company, Llc | Process for preventing or mitigating biofouling |
| US11497720B2 (en) * | 2010-12-09 | 2022-11-15 | Septeos | Pharmaceutical composition comprising trans-cinnamaldehyde and its use in the treatment of infections |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1297510B1 (en) * | 1997-12-23 | 1999-12-17 | Consortia Lab Srl | COLORIMETRIC METHOD TO ASSESS THE SENSITIVITY OF HELICOBACTER PYLORI TO ANTIMICROBIAL SUBSTANCES AND KITS TO IMPLEMENT THIS METHOD. |
| US6488838B1 (en) | 1999-08-17 | 2002-12-03 | Battelle Memorial Institute | Chemical reactor and method for gas phase reactant catalytic reactions |
| CN102861001B (en) * | 2012-10-17 | 2018-07-24 | 中国人民解放军第四军医大学 | Novel application of cinnamic aldehyde for treating gastritis |
| WO2016108774A1 (en) | 2014-12-31 | 2016-07-07 | Izmir Teknoloji Gelistirme Bolgesi A. S. | Essential oil loaded mucoadhesive nanocomposite delivery system for gastrointestinal system |
| CN106420734B (en) * | 2016-09-22 | 2019-08-02 | 河南科技学院 | A kind of scavenger for killing staphylococcus aureus persister rest cell |
| CN112716840A (en) * | 2020-12-29 | 2021-04-30 | 李雪静 | Composition for inhibiting helicobacter pylori, preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4202877A (en) * | 1977-11-21 | 1980-05-13 | Kureha Kagaku Kogyo Kabushiki Kaisha | Antidermatomycotic agent |
| US4888417A (en) * | 1985-05-25 | 1989-12-19 | Green Cross Corporation | Therapeutic and prophylactic agents for peptic ulcer |
| EP0577481A1 (en) * | 1992-06-25 | 1994-01-05 | Technion Research & Development Foundation Ltd. | New therapeutic application of a Thyme extract and in-vitro methods for inhibiting the growth and urease activity of Helicobacter pylori |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57179522A (en) * | 1981-04-27 | 1982-11-05 | Hitachi Ltd | Deodorizing filter for air conditioner |
| JPS59175410A (en) * | 1983-03-26 | 1984-10-04 | Kanebo Shokuhin Kk | Cariostatic agent |
| JPH0645549B2 (en) * | 1990-05-24 | 1994-06-15 | 株式会社ロッテ | Anti periodontal drug |
-
1994
- 1994-06-27 US US08/266,013 patent/US5560912A/en not_active Expired - Fee Related
- 1994-06-29 EP EP94401473A patent/EP0689842A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4202877A (en) * | 1977-11-21 | 1980-05-13 | Kureha Kagaku Kogyo Kabushiki Kaisha | Antidermatomycotic agent |
| US4888417A (en) * | 1985-05-25 | 1989-12-19 | Green Cross Corporation | Therapeutic and prophylactic agents for peptic ulcer |
| EP0577481A1 (en) * | 1992-06-25 | 1994-01-05 | Technion Research & Development Foundation Ltd. | New therapeutic application of a Thyme extract and in-vitro methods for inhibiting the growth and urease activity of Helicobacter pylori |
Non-Patent Citations (15)
| Title |
|---|
| Andrew H. Soll, "Pathogenesis Of Peptic Ulcer And Implications For Therapy". The New England Journal Of Medicine, Mar. 29, 1990, pp. 909-916. |
| Andrew H. Soll, Pathogenesis Of Peptic Ulcer And Implications For Therapy . The New England Journal Of Medicine, Mar. 29, 1990, pp. 909 916. * |
| Barry J. Marshall et al. "Pyloric campylobacter Infection And Gastroduodenal Disease". Medical Journal of Australia, Apr. 15, 1995, vol. 142, pp. 439-443. |
| Barry J. Marshall et al. Pyloric campylobacter Infection And Gastroduodenal Disease . Medical Journal of Australia, Apr. 15, 1995, vol. 142, pp. 439 443. * |
| E. F. Steinmetz, Cotex Vegetabilis 1957. * |
| Gabriele Geis et al., "Unusual Fatty Acid Substitution in Lipids and Lipopolysaccharides of Helicobacter pylori", Journal of Microbiology, May 1990, pp. 930-932. |
| Gabriele Geis et al., Unusual Fatty Acid Substitution in Lipids and Lipopolysaccharides of Helicobacter pylori , Journal of Microbiology, May 1990, pp. 930 932. * |
| H. G. Desai et al., "Dental Plaque: A Permanent Reservoir of Helicobacter pylori?", Scand. J. Gastroenterol 1991, 26, pp. 1205-1208. |
| H. G. Desai et al., Dental Plaque: A Permanent Reservoir of Helicobacter pylori , Scand. J. Gastroenterol 1991, 26, pp. 1205 1208. * |
| K. Rosberg et al., "Adhesion of Helicobacter pylori to Human Gastric Mucosal Biopsy Specimens Cultivated in Vitro", Scand. J. Gastroenterol 1991, 26, pp. 1179-1187. |
| K. Rosberg et al., Adhesion of Helicobacter pylori to Human Gastric Mucosal Biopsy Specimens Cultivated in Vitro , Scand. J. Gastroenterol 1991, 26, pp. 1179 1187. * |
| Laura L. George et al. "Cure Of Duodenal Ulcer After Eradication Of Helicobacter pylori". Medical Journal Of Australia, Aug. 6, 1990, vol. 153, pp. 145-149. |
| Laura L. George et al. Cure Of Duodenal Ulcer After Eradication Of Helicobacter pylori . Medical Journal Of Australia, Aug. 6, 1990, vol. 153, pp. 145 149. * |
| Laura L. Zaika, "Spices and Herbs: Their Antimicrobial Activity and Its Determination", Journal of Food Safety 9, 1988, pp. 97-118. |
| Laura L. Zaika, Spices and Herbs: Their Antimicrobial Activity and Its Determination , Journal of Food Safety 9, 1988, pp. 97 118. * |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6428808B1 (en) * | 1995-05-23 | 2002-08-06 | Smithkline Beecham P.L.C. | Pharmaceutical composition prepared by addition of a flavor vehicle to a medicament |
| US6187313B1 (en) | 1996-03-26 | 2001-02-13 | Nature's Sunshine Products, Inc. | Composition and method for treating and preventing helicobactor-pylori-associated stomach gastritis, ulcers and cancer |
| US5753711A (en) * | 1997-03-18 | 1998-05-19 | Collagenex Pharmaceuticals, Inc. | Method for treatment of H. pylori |
| DE19711597A1 (en) * | 1997-03-20 | 1998-09-24 | Pascoe Pharm Praeparate Gmbh | Preparation for treating Helicobacter pylori infections |
| DE19711597C2 (en) * | 1997-03-20 | 1999-05-06 | Pascoe Pharm Praeparate Gmbh | Medicinal preparation for the eradication of an infection with Helicobacter pylori |
| US6248551B1 (en) * | 1997-03-28 | 2001-06-19 | Institut Pasteur | Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides |
| US6350468B1 (en) | 1997-12-17 | 2002-02-26 | Axcan Pharma Inc. | Double capsule for the administration of active principles in multiple therapies |
| US7517666B2 (en) | 1998-06-30 | 2009-04-14 | Institut Pasteur | Methods of inhibiting Helicobacter pylori |
| US20050176077A1 (en) * | 1998-06-30 | 2005-08-11 | Institut Pasteur | Methods of inhibiting Helicobacter pylori |
| US6190667B1 (en) * | 1998-06-30 | 2001-02-20 | Institut Pasteur | Methods of inhibiting Helicobacter pylori |
| US6416968B1 (en) | 1998-06-30 | 2002-07-09 | Institut Pasteur | Methods of inhibiting Helicobacter pylori |
| US20040115772A1 (en) * | 1998-06-30 | 2004-06-17 | Hilde De Reuse | Methods of inhibiting Helicobacter pylori |
| US6762051B2 (en) | 1998-06-30 | 2004-07-13 | Institut Pasteur | Methods of inhibiting helicobacter pylori |
| US6638523B1 (en) * | 1999-10-27 | 2003-10-28 | Nagase & Company, Ltd. | Method of treating ulcers |
| US20050008690A1 (en) * | 2002-04-10 | 2005-01-13 | Miller Fred H. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US8361497B2 (en) | 2002-04-10 | 2013-01-29 | Innercap Technologies, Inc. | Multi-phase, multi-compartment, capsular delivery apparatus and methods for using the same |
| US20040009956A1 (en) * | 2002-04-29 | 2004-01-15 | Dehua Pei | Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic |
| US20110195938A1 (en) * | 2010-02-09 | 2011-08-11 | Baker Hughes Incorporated | Process for preventing or mitigating biofouling |
| US10174239B2 (en) | 2010-02-09 | 2019-01-08 | Baker Hughes, A Ge Company, Llc | Process for preventing or mitigating biofouling |
| US11497720B2 (en) * | 2010-12-09 | 2022-11-15 | Septeos | Pharmaceutical composition comprising trans-cinnamaldehyde and its use in the treatment of infections |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0689842A1 (en) | 1996-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5560912A (en) | Method for inhibiting growth of helicobacter pylori | |
| Tabak et al. | In vitro inhibition of Helicobacter pylori by extracts of thyme | |
| CA2115381C (en) | Rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori | |
| Tabak et al. | Cinnamon extracts’ inhibitory effect on Helicobacter pylori | |
| Knudsen et al. | Carbenicillin: a new semisynthetic penicillin active against Pseudomonas pyocyanea | |
| Dooley et al. | Antibiotics in the treatment of biliary infection | |
| US5472695A (en) | Therapeutic application of a thyme extract and in - vitro methods for inhibiting the growth and urease activity of helicobacter pylori | |
| CA2344308C (en) | Taurolidine and/or taurultam against infectious ulcer or gastritis | |
| RU2104710C1 (en) | Pharmaceutical bactericidal compositions and their using | |
| Nøorgaard et al. | Neutrophil degranulation by Helicobacter pylori proteins. | |
| Koga et al. | In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori | |
| May et al. | Amoxicillin in the treatment of infections of the lower respiratory tract | |
| EP2236148B1 (en) | Cgnc for use in treating h. pylori infection | |
| EP0577481B1 (en) | New therapeutic application of a Thyme extract and in-vitro methods for inhibiting the growth and urease activity of Helicobacter pylori | |
| JP4307263B2 (en) | Active cereal products effective against OGIP infection | |
| Ngwa et al. | Isolation, characterisation and evaluation of antiulcerogenic potentials of probiotic lactic acid bacteria isolated from fermented milk and palm wine against ethanol-induced gastric ulcer in mice | |
| CN111744016B (en) | Application of Compound Amino Acids in Preparation of Drugs for Improving Bacterial Sensitivity to Antibiotics | |
| Hitchcock et al. | Gas gangrene infections of the small intestine, colon and rectum | |
| US4959384A (en) | Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders | |
| JPH0827017A (en) | Chemical composition for inhibiting growth of helicobuctor pyroli | |
| ROBERTS et al. | Demethylchlortetracycline and Tetracycline: A Critical Comparison: In Vitro Activity, Serum Concentrations, and Effect of Serum Binding | |
| IL102708A (en) | Pharmaceutical compositions containing cinnamon extract for inhibiting growth of helicobacter pylori | |
| Tucci et al. | Weekend Therapy for the Treatment ofHelicobacter pyloriInfection | |
| RU2150271C1 (en) | Method for treating the cases of chronic prostatitis, gastric and duodenal peptic ulcer | |
| Leigh | Diagnosis of urinary tract infections in general practice, and treatment with a new penicillin—amoxycillin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD., I Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NEEMAN, ITZHAK;TABAK, MINA;ARMON, ROBERT;REEL/FRAME:008369/0075 Effective date: 19960425 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| SULP | Surcharge for late payment | ||
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20041001 |